149 related articles for article (PubMed ID: 2167038)
21. Amino acid substitutions in GyrA affect quinolone susceptibility in Salmonella typhimurium.
Kongsoi S; Changkwanyeun R; Yokoyama K; Nakajima C; Changkaew K; Suthienkul O; Suzuki Y
Drug Test Anal; 2016 Oct; 8(10):1065-1070. PubMed ID: 26514939
[TBL] [Abstract][Full Text] [Related]
22. Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis.
Revel-Viravau V; Truong QC; Moreau N; Jarlier V; Sougakoff W
Antimicrob Agents Chemother; 1996 Sep; 40(9):2054-61. PubMed ID: 8878580
[TBL] [Abstract][Full Text] [Related]
23. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.
Hooper DC; Wolfson JS; Souza KS; Ng EY; McHugh GL; Swartz MN
Antimicrob Agents Chemother; 1989 Mar; 33(3):283-90. PubMed ID: 2658782
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of AT-4140 against clinical bacterial isolates.
Kojima T; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1989 Nov; 33(11):1980-8. PubMed ID: 2558617
[TBL] [Abstract][Full Text] [Related]
26. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium.
Gensberg K; Jin YF; Piddock LJ
FEMS Microbiol Lett; 1995 Oct; 132(1-2):57-60. PubMed ID: 7590165
[TBL] [Abstract][Full Text] [Related]
27. Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424.
Pace J; Bertasso A; Georgopapadakou NH
Antimicrob Agents Chemother; 1991 May; 35(5):910-5. PubMed ID: 1649574
[TBL] [Abstract][Full Text] [Related]
28. Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB.
Hooper DC; Wolfson JS; Bozza MA; Ng EY
Antimicrob Agents Chemother; 1992 May; 36(5):1151-4. PubMed ID: 1510409
[TBL] [Abstract][Full Text] [Related]
29. Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12.
Chow RT; Dougherty TJ; Fraimow HS; Bellin EY; Miller MH
Antimicrob Agents Chemother; 1988 Aug; 32(8):1113-8. PubMed ID: 3056251
[TBL] [Abstract][Full Text] [Related]
30. Salmonella typhimurium gyrA mutations associated with fluoroquinolone resistance.
Reyna F; Huesca M; González V; Fuchs LY
Antimicrob Agents Chemother; 1995 Jul; 39(7):1621-3. PubMed ID: 7492118
[TBL] [Abstract][Full Text] [Related]
31. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.
Hoshino K; Kitamura A; Morrissey I; Sato K; Kato J; Ikeda H
Antimicrob Agents Chemother; 1994 Nov; 38(11):2623-7. PubMed ID: 7872758
[TBL] [Abstract][Full Text] [Related]
32. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
Yoshida T; Mitsuhashi S
Antimicrob Agents Chemother; 1993 Apr; 37(4):793-800. PubMed ID: 8388199
[TBL] [Abstract][Full Text] [Related]
33. Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones.
Bazile S; Moreau N; Bouzard D; Essiz M
Antimicrob Agents Chemother; 1992 Dec; 36(12):2622-7. PubMed ID: 1336340
[TBL] [Abstract][Full Text] [Related]
34. Resistance to fluoroquinolones in Escherichia coli isolated from poultry.
Bazile-Pham-Khac S; Truong QC; Lafont JP; Gutmann L; Zhou XY; Osman M; Moreau NJ
Antimicrob Agents Chemother; 1996 Jun; 40(6):1504-7. PubMed ID: 8726027
[TBL] [Abstract][Full Text] [Related]
35. A class of gyrase mutants of Salmonella typhimurium show quinolone-like lethality and require rec functions for viability.
Garí E; Figueroa-Bossi N; Blanc-Potard AB; Spirito F; Schmid MB; Bossi L
Mol Microbiol; 1996 Jul; 21(1):111-22. PubMed ID: 8843438
[TBL] [Abstract][Full Text] [Related]
36. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.
Akasaka T; Kurosaka S; Uchida Y; Tanaka M; Sato K; Hayakawa I
Antimicrob Agents Chemother; 1998 May; 42(5):1284-7. PubMed ID: 9593169
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.
Wu P; Lawrence LE; Denbleyker KL; Barrett JF
Antimicrob Agents Chemother; 2001 Dec; 45(12):3660-2. PubMed ID: 11709365
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition.
Denis A; Moreau NJ
J Antimicrob Chemother; 1993 Sep; 32(3):379-92. PubMed ID: 8262860
[TBL] [Abstract][Full Text] [Related]
39. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
[TBL] [Abstract][Full Text] [Related]
40. Relationship between the expression of ompF and quinolone resistance in Escherichia coli.
Kishii R; Takei M
J Infect Chemother; 2009 Dec; 15(6):361-6. PubMed ID: 20012725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
